GlobeNewsWire
12 Jun 2026, 16:45 UTC · 13w ago
Verdict
Headline takes no side. We score LYEL +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Ronde-cel demonstrated no Grade 3 or higher cytokine release syndrome (CRS) and low rates of Grade 3 or higher ICANS in 108 patients.
More positive than 91% of claims this week
Lyell expects to submit a Biologics License Application (BLA) for ronde-cel in the second half of 2027.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 84% of claims this week
The manufacturing process for ronde-cel has achieved a 97% success rate to date.
More positive than 76% of claims this week
Translational data indicate that durable responses are linked to CD62L-enriched CAR T-cells with an enhanced memory phenotype.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company announced positive safety data, high manufacturing success rates, and supportive translational insights for its CAR T-cell therapy candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
56m ago
−22.6%
Price is moving against the score
$10.62 vs $13.72 close before publication (Jun 11) · not market-adjusted
LYEL chart →
